Q2 2026 delivered 19% revenue growth, strong global adoption of da Vinci and Ion platforms, and robust capital placements. Guidance for 2026 procedure growth and margins was maintained or raised, with continued innovation and expansion in key markets despite challenges in China and Europe.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.